GUIZHOU YIBAI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.92 CNY | -4.39% |
|
-4.16% | -31.11% |
| Apr. 18 | Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 2023 | YiBai Pharma to Repurchase Up to 40 Million Yuan Shares | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4,371 | 3,944 | 4,134 | 6,438 | 4,379 | 4,506 |
| Enterprise Value (EV) 1 | 5,348 | 4,220 | 4,599 | 6,971 | 4,874 | 4,807 |
| P/E ratio | -6.03 x | 27.8 x | 18.1 x | 26.4 x | -10.3 x | 43.4 x |
| Yield | - | 6.02% | 8.24% | - | - | 1.16% |
| Capitalization / Revenue | 1.13 x | 1.17 x | 1.21 x | 1.92 x | 1.6 x | 1.6 x |
| EV / Revenue | 1.38 x | 1.26 x | 1.35 x | 2.08 x | 1.78 x | 1.7 x |
| EV / EBITDA | 11 x | 9.41 x | 7.57 x | 12 x | 12.3 x | 13.2 x |
| EV / FCF | -6.18 x | 7.54 x | 59.2 x | 24.1 x | -39.3 x | 28.7 x |
| FCF Yield | -16.2% | 13.3% | 1.69% | 4.14% | -2.54% | 3.49% |
| Price to Book | 1.25 x | 1.1 x | 1.23 x | 1.84 x | 1.44 x | 1.47 x |
| Nbr of stocks (in thousands) | 791,927 | 791,927 | 791,927 | 791,927 | 791,927 | 791,927 |
| Reference price 2 | 5.520 | 4.980 | 5.220 | 8.130 | 5.530 | 5.690 |
| Announcement Date | 4/29/19 | 4/28/20 | 4/22/21 | 4/22/22 | 4/27/23 | 4/18/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 3,883 | 3,361 | 3,413 | 3,347 | 2,735 | 2,821 |
| EBITDA 1 | 487.6 | 448.6 | 607.6 | 580.7 | 395.1 | 363.4 |
| EBIT 1 | 308.3 | 296 | 466.7 | 433.1 | 223.1 | 171.8 |
| Operating Margin | 7.94% | 8.81% | 13.67% | 12.94% | 8.16% | 6.09% |
| Earnings before Tax (EBT) 1 | -785.9 | 208.3 | 297.5 | 310.4 | -392.1 | 132.3 |
| Net income 1 | -725.5 | 141.9 | 228.8 | 243.8 | -426.5 | 103.4 |
| Net margin | -18.68% | 4.22% | 6.7% | 7.28% | -15.59% | 3.67% |
| EPS 2 | -0.9160 | 0.1790 | 0.2890 | 0.3080 | -0.5390 | 0.1310 |
| Free Cash Flow 1 | -864.8 | 559.9 | 77.65 | 288.9 | -124 | 167.8 |
| FCF margin | -22.27% | 16.66% | 2.27% | 8.63% | -4.53% | 5.95% |
| FCF Conversion (EBITDA) | - | 124.8% | 12.78% | 49.76% | - | 46.16% |
| FCF Conversion (Net income) | - | 394.57% | 33.94% | 118.52% | - | 162.26% |
| Dividend per Share | - | 0.3000 | 0.4300 | - | - | 0.0660 |
| Announcement Date | 4/29/19 | 4/28/20 | 4/22/21 | 4/22/22 | 4/27/23 | 4/18/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 976 | 276 | 465 | 532 | 495 | 301 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.003 x | 0.6153 x | 0.7653 x | 0.917 x | 1.252 x | 0.8275 x |
| Free Cash Flow 1 | -865 | 560 | 77.6 | 289 | -124 | 168 |
| ROE (net income / shareholders' equity) | -15.8% | 3.47% | 5.88% | 6.57% | -13% | 2.86% |
| ROA (Net income/ Total Assets) | 2.82% | 3.06% | 5.38% | 5.26% | 2.81% | 2.23% |
| Assets 1 | -25,738 | 4,638 | 4,253 | 4,635 | -15,191 | 4,646 |
| Book Value Per Share 2 | 4.420 | 4.550 | 4.250 | 4.420 | 3.840 | 3.870 |
| Cash Flow per Share 2 | 0.7000 | 1.350 | 0.7900 | 0.4800 | 0.7500 | 0.8800 |
| Capex 1 | 321 | 201 | 396 | 448 | 323 | 130 |
| Capex / Sales | 8.28% | 5.99% | 11.59% | 13.38% | 11.81% | 4.62% |
| Announcement Date | 4/29/19 | 4/28/20 | 4/22/21 | 4/22/22 | 4/27/23 | 4/18/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -31.11% | 450M | |
| +34.35% | 693B | |
| +29.39% | 584B | |
| -3.49% | 372B | |
| +20.15% | 332B | |
| +6.19% | 294B | |
| +14.11% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +9.21% | 168B |
- Stock Market
- Equities
- 600594 Stock
- Financials Guizhou Yibai Pharmaceutical Co., Ltd.